CU20190015A7 - Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden - Google Patents
Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprendenInfo
- Publication number
- CU20190015A7 CU20190015A7 CU2019000015A CU20190015A CU20190015A7 CU 20190015 A7 CU20190015 A7 CU 20190015A7 CU 2019000015 A CU2019000015 A CU 2019000015A CU 20190015 A CU20190015 A CU 20190015A CU 20190015 A7 CU20190015 A7 CU 20190015A7
- Authority
- CU
- Cuba
- Prior art keywords
- masp
- low viscosity
- composition
- pharmaceutical compositions
- antibody formulations
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 101710117460 Mannan-binding lectin serine protease 2 Proteins 0.000 title abstract 2
- 102100026046 Mannan-binding lectin serine protease 2 Human genes 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 101001056015 Homo sapiens Mannan-binding lectin serine protease 2 Proteins 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000054960 human MASP2 Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
<p>La presente invención se refiere a formulaciones de anticuerpos inhibidores de MASP-2 estables, de alta concentración y de baja viscosidad que comprenden una solución acuosa que comprende un sistema tampón que tiene un pH de 5.0 a 7.0 y un anticuerpo monoclonal o fragmento del mismo que se une específicamente a MASP-2 humano a una concentración de aproximadamente 50mg/ml hasta aproximadamente 250 mg/ml; en donde la formulación tiene una viscosidad de entre 2 y 50 centipose y en donde la formulación es estable cuando se almacena entre 2 ºC y 8 ºC durante al menos un mes.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662382156P | 2016-08-31 | 2016-08-31 | |
| PCT/US2017/049415 WO2018045054A1 (en) | 2016-08-31 | 2017-08-30 | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20190015A7 true CU20190015A7 (es) | 2019-11-04 |
Family
ID=61301617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2019000015A CU20190015A7 (es) | 2016-08-31 | 2017-08-30 | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11628217B2 (es) |
| EP (1) | EP3506886B1 (es) |
| JP (2) | JP6864747B2 (es) |
| KR (2) | KR20190043161A (es) |
| CN (3) | CN116327917A (es) |
| AR (1) | AR109494A1 (es) |
| AU (2) | AU2017321605B2 (es) |
| BR (1) | BR112019003479A2 (es) |
| CA (1) | CA3035252C (es) |
| CL (1) | CL2019000508A1 (es) |
| CO (1) | CO2019002239A2 (es) |
| CR (1) | CR20190150A (es) |
| CU (1) | CU20190015A7 (es) |
| EA (1) | EA201990598A1 (es) |
| EC (1) | ECSP19021312A (es) |
| GE (1) | GEP20217252B (es) |
| IL (1) | IL265071B2 (es) |
| JO (1) | JOP20170170B1 (es) |
| MA (1) | MA46109A (es) |
| MX (1) | MX2019002338A (es) |
| MY (1) | MY189411A (es) |
| PE (1) | PE20190469A1 (es) |
| PH (1) | PH12019500365A1 (es) |
| SG (2) | SG10202100697PA (es) |
| TW (2) | TWI719245B (es) |
| UA (1) | UA122733C2 (es) |
| UY (1) | UY37391A (es) |
| WO (1) | WO2018045054A1 (es) |
| ZA (1) | ZA201901891B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017205453B2 (en) * | 2016-01-05 | 2020-03-12 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| BR112020003632A2 (pt) * | 2017-08-25 | 2020-10-27 | Omeros Corporation | método de tratamento de um indivíduo que sofre ou corre risco de desenvolver ahus |
| CA3129901A1 (en) | 2019-02-18 | 2020-08-27 | Eli Lilly And Company | Therapeutic antibody formulation |
| WO2021013689A1 (en) * | 2019-07-19 | 2021-01-28 | Ichnos Sciences SA | Lyophilized antibody formulation |
| CA3159159A1 (en) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Masp-2 inhibitors and methods of use |
| AU2020398241A1 (en) | 2019-12-04 | 2022-06-30 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| EP4069238A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| IL293551A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
| KR20230042744A (ko) | 2020-07-31 | 2023-03-29 | 알라맵 테라퓨틱스, 인크. | 항-코넥신 항체 제제 |
| US20230406920A1 (en) * | 2020-10-22 | 2023-12-21 | Allakos Inc. | Anti-siglec-8 antibody formulations |
| CA3221859A1 (en) * | 2021-06-08 | 2022-12-15 | Xiaowu Liu | Anti-masp-2 antibody and use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CN101378782A (zh) | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| CA2971474C (en) | 2009-10-16 | 2022-11-22 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| NZ709997A (en) | 2011-04-08 | 2016-03-31 | Univ Leicester | Methods for treating conditions associated with masp-2 dependent complement activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20150166676A1 (en) * | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| MX367097B (es) * | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| ME03755B (me) * | 2011-05-04 | 2021-04-20 | Omeros Corp | Kompozicije za inhibiciju masp-2 zavisne aktivacije komplementa |
| RS61755B1 (sr) * | 2012-06-18 | 2021-05-31 | Omeros Corp | Kompozicije i postupci za inhibiciju masp-1 i/ili masp-2 i/ili masp-3 za tretman različitih bolesti i poremećaja |
| WO2014141149A1 (en) | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations with reduced viscosity |
| ES2829913T3 (es) | 2013-10-17 | 2021-06-02 | Omeros Corp | Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2 |
| AU2015310879A1 (en) * | 2014-09-03 | 2017-03-02 | Medimmune Limited | Stable anti-IL-4R-alpha antibody formulation |
| JP2018500380A (ja) | 2014-12-31 | 2018-01-11 | ノベルメド セラピューティクス，インコーポレーテッド | アグリコシル化治療用抗体の製剤 |
| GEP20247583B (en) | 2015-11-09 | 2024-01-10 | Univ Leicester | Methods for treating condi tions associated with masp-2 dependent complement activation |
| AU2017205453B2 (en) | 2016-01-05 | 2020-03-12 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| US20170253667A1 (en) | 2016-01-05 | 2017-09-07 | University Of Leicester | Methods for inhibiting fibrosis in a subject in need thereof |
| US10870708B2 (en) | 2016-03-31 | 2020-12-22 | University Of Leicester | Methods for inhibiting angiogenesis in a subject in need thereof |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
-
2017
- 2017-08-28 JO JOP/2017/0170A patent/JOP20170170B1/ar active
- 2017-08-29 TW TW106129287A patent/TWI719245B/zh active
- 2017-08-29 TW TW108111015A patent/TWI730310B/zh active
- 2017-08-30 PE PE2019000408A patent/PE20190469A1/es unknown
- 2017-08-30 CN CN202210971376.1A patent/CN116327917A/zh active Pending
- 2017-08-30 MA MA046109A patent/MA46109A/fr unknown
- 2017-08-30 CU CU2019000015A patent/CU20190015A7/es unknown
- 2017-08-30 SG SG10202100697PA patent/SG10202100697PA/en unknown
- 2017-08-30 SG SG11201901444PA patent/SG11201901444PA/en unknown
- 2017-08-30 MY MYPI2019000424A patent/MY189411A/en unknown
- 2017-08-30 GE GEAP201715038A patent/GEP20217252B/en unknown
- 2017-08-30 EP EP17847485.4A patent/EP3506886B1/en active Active
- 2017-08-30 JP JP2019531596A patent/JP6864747B2/ja active Active
- 2017-08-30 MX MX2019002338A patent/MX2019002338A/es unknown
- 2017-08-30 BR BR112019003479-0A patent/BR112019003479A2/pt active Search and Examination
- 2017-08-30 WO PCT/US2017/049415 patent/WO2018045054A1/en active Application Filing
- 2017-08-30 CR CR20190150A patent/CR20190150A/es unknown
- 2017-08-30 KR KR1020197008678A patent/KR20190043161A/ko not_active IP Right Cessation
- 2017-08-30 CN CN201780051640.7A patent/CN109890367B/zh active Active
- 2017-08-30 UA UAA201903034A patent/UA122733C2/uk unknown
- 2017-08-30 IL IL265071A patent/IL265071B2/en unknown
- 2017-08-30 CA CA3035252A patent/CA3035252C/en active Active
- 2017-08-30 US US15/691,266 patent/US11628217B2/en active Active
- 2017-08-30 EA EA201990598A patent/EA201990598A1/ru unknown
- 2017-08-30 AU AU2017321605A patent/AU2017321605B2/en active Active
- 2017-08-30 CN CN202210971401.6A patent/CN116327695A/zh active Pending
- 2017-08-30 KR KR1020217035424A patent/KR102444154B1/ko active IP Right Grant
- 2017-08-31 UY UY0001037391A patent/UY37391A/es unknown
- 2017-08-31 AR ARP170102432A patent/AR109494A1/es unknown
-
2019
- 2019-02-20 PH PH12019500365A patent/PH12019500365A1/en unknown
- 2019-02-26 CL CL2019000508A patent/CL2019000508A1/es unknown
- 2019-03-11 CO CONC2019/0002239A patent/CO2019002239A2/es unknown
- 2019-03-27 ZA ZA2019/01891A patent/ZA201901891B/en unknown
- 2019-03-27 EC ECSENADI201921312A patent/ECSP19021312A/es unknown
-
2020
- 2020-11-24 AU AU2020277135A patent/AU2020277135B2/en active Active
-
2021
- 2021-04-02 JP JP2021063245A patent/JP7197623B2/ja active Active
-
2023
- 2023-02-28 US US18/176,155 patent/US20230226178A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| AR127361A2 (es) | Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| CL2019002478A1 (es) | Formulación de anticuerpo monoclonal anti-vrs. | |
| BR112018067792A2 (pt) | preparação contendo o anticorpo | |
| ECSP077261A (es) | Composición de anticuerpo her2 | |
| UY38080A (es) | FORMULACIÓN FARMACÉUTICA DE pH BAJO | |
| EA201792273A1 (ru) | Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела | |
| BR112017003419A2 (pt) | formulação de anticorpo anti-il-4r-alfa estável | |
| NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| MX2021002935A (es) | Formulacion de anticuerpos contra csf-1r. | |
| CL2019003032A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. | |
| BR112019024785A2 (pt) | composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso | |
| AR117407A1 (es) | Formulaciones acuosas estables de anticuerpos anti-tau | |
| CO7270463A2 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición | |
| AR108631A1 (es) | Formulación de neurotoxinas | |
| CO2020006120A2 (es) | Formulación | |
| BR112024002019A2 (pt) | Compostos de pirimidina e uso dos mesmos | |
| CO2020013545A2 (es) | Formulación estable de anticuerpos | |
| AR114360A1 (es) | FORMULACIÓN FARMACEUTICA DE pH BAJO | |
| BR112022002094A2 (pt) | Composição imunogênica | |
| AR127421A1 (es) | Formulaciones farmacéuticas que comprenden anticuerpos anti-tg2. |